Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


11.02.2019

1 Am J Clin Oncol
1 Anticancer Res
2 BJU Int
1 BMC Urol
1 Br J Radiol
1 Cancer
1 Cancer Lett
1 Cancer Res
6 Eur Urol
1 Int J Oncol
3 Int J Radiat Oncol Biol Phys
23 J Urol
2 Lancet Oncol
1 Nat Rev Urol
2 Oncogene
3 PLoS One
2 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. FOSTER B, Jackson W, Foster C, Dess R, et al
    Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.
    Am J Clin Oncol. 2019 Feb 4. doi: 10.1097/COC.0000000000000521.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. KUROSE H, Ueda K, Kondo R, Ogasawara S, et al
    Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
    Anticancer Res. 2019;39:957-964.
    PubMed     Text format     Abstract available


    BJU Int

  3. KAM J, Yuminaga Y, Krelle M, Gavin D, et al
    How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study.
    BJU Int. 2019 Feb 3. doi: 10.1111/bju.14696.
    PubMed     Text format     Abstract available

  4. LIGHT A, Elhage O, Marconi L, Dasgupta P, et al
    Prostate cancer screening: where are we now?
    BJU Int. 2019 Feb 5. doi: 10.1111/bju.14692.
    PubMed     Text format     Abstract available


    BMC Urol

  5. BREAU RH, Kumar RM, Lavallee LT, Cagiannos I, et al
    The effect of surgery report cards on improving radical prostatectomy quality: the SuRep study protocol.
    BMC Urol. 2018;18:89.
    PubMed     Text format     Abstract available


    Br J Radiol

  6. WANG H, Cooper BT, Schiff P, Sanfilippo NJ, et al
    Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans.
    Br J Radiol. 2019;92:20180471.
    PubMed     Text format     Abstract available


    Cancer

  7. AGGARWAL AK, Sujenthiran A, Lewis D, Walker K, et al
    Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national population-based study.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31987.
    PubMed     Text format     Abstract available


    Cancer Lett

  8. NIKHIL K, Chang L, Viccaro K, Jacobsen M, et al
    Identification of LIMK2 as a Therapeutic Target in Castration Resistant Prostate Cancer.
    Cancer Lett. 2019 Feb 1. pii: S0304-3835(19)30055.
    PubMed     Text format     Abstract available


    Cancer Res

  9. WU L, Yi B, Wei S, Yao D, et al
    Loss of Foxp3 and Tsc1 Accelerate Prostate Cancer Progression through a Synergistic Transcriptional and Post-translational Regulation of c-MYC.
    Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2049.
    PubMed     Text format     Abstract available


    Eur Urol

  10. VALE S
    Re: Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol 2019;75:3-7: Translati
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30089.
    PubMed     Text format    

  11. SHOAG JE, Tosoian JJ, Salami SS, Barbieri CE, et al
    Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30070.
    PubMed     Text format    

  12. VOLTA AD, Formenti A, Berruti A
    Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
    Eur Urol. 2019 Jan 30. pii: S0302-2838(19)30069.
    PubMed     Text format     Abstract available

  13. LOEB S, Taylor J, Butaney M, Byrne NK, et al
    Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.
    Eur Urol. 2019 Jan 30. pii: S0302-2838(19)30068.
    PubMed     Text format    

  14. KEARNS JT, Newcomb LF, Lin DW
    Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Stud
    Eur Urol. 2018;74:e151.
    PubMed     Text format    

  15. YUAN R
    Re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12.
    Eur Urol. 2018;74:e149-e150.
    PubMed     Text format    


    Int J Oncol

  16. KURODA K, Liu H
    The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
    Int J Oncol. 2019 Feb 1. doi: 10.3892/ijo.2019.4706.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. POTTERS L, Rana Z, Lee L, Cox BW, et al
    Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II trial for Patients with Low and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30183.
    PubMed     Text format     Abstract available

  18. ABU-GHEIDA I, Reddy CA, Kotecha R, Weller MA, et al
    Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30182.
    PubMed     Text format     Abstract available

  19. MYLONA E, Acosta O, Lizee T, Lafond C, et al
    Voxel-based analysis for identification of urethro-vesical subregions predicting urinary toxicity after prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys. 2019 Feb 1. pii: S0360-3016(19)30179.
    PubMed     Text format     Abstract available


    J Urol

  20. EGGENER S
    Editorial Comment.
    J Urol. 2019;201:266-267.
    PubMed     Text format    

  21. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2019;201:119.
    PubMed     Text format    

  22. STERNBERG IA
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed     Text format    

  23. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed     Text format    

  24. GLASER ZA, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2019;201:90.
    PubMed     Text format    

  25. PUNNEN S
    Editorial Comment.
    J Urol. 2019;201:83.
    PubMed     Text format    

  26. PERLIS N
    Editorial Comment.
    J Urol. 2019;201:82.
    PubMed     Text format    

  27. RESNICK MJ
    Editorial Comment.
    J Urol. 2018;200:80-81.
    PubMed     Text format    

  28. HUEN KH, Bergman J
    Editorial Comment.
    J Urol. 2018;200:80.
    PubMed     Text format    

  29. ROSENKRANTZ AB, Hemingway J, Hughes DR, Duszak R Jr, et al
    Evolving Use of Prebiopsy Prostate Magnetic Resonance Imaging in the Medicare Population.
    J Urol. 2018;200:89-94.
    PubMed     Text format     Abstract available

  30. MOSES KA
    Editorial Comment.
    J Urol. 2019;201:267.
    PubMed     Text format    

  31. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:276.
    PubMed     Text format    

  32. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:277.
    PubMed     Text format    

  33. DAS S, Salami SS, Spratt DE, Kaffenberger SD, et al
    Bringing prostate cancer germline genetics into clinical practice.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000137.
    PubMed     Text format     Abstract available

  34. FALAGARIO UG, Beksac AT, Martini A, Cumarasamy S, et al
    Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
    J Urol. 2019 Feb 4. doi: 10.1097/JU.0000000000000134.
    PubMed     Text format     Abstract available

  35. BOTEJUE M, Abbott D, Danella J, Fonshell C, et al
    Utilization of Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    J Urol. 2019 Jan 31. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  36. TILKI D
    Editorial Comment.
    J Urol. 2019;201:340.
    PubMed     Text format    

  37. SCARSBROOK A
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed     Text format    

  38. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed     Text format    

  39. THOMPSON JE, Stricker PD
    Editorial Comment.
    J Urol. 2019;201:306-307.
    PubMed     Text format    

  40. CARROLL P
    Editorial Comment.
    J Urol. 2019;201:298-299.
    PubMed     Text format    

  41. CHUA MLK
    Editorial Comment.
    J Urol. 2019;201:291.
    PubMed     Text format    

  42. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:290-291.
    PubMed     Text format    


    Lancet Oncol

  43. DOWNING A, Wright P, Hounsome L, Selby P, et al
    Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
    Lancet Oncol. 2019 Jan 31. pii: S1470-2045(18)30780.
    PubMed     Text format     Abstract available

  44. SAAD F
    Quality of life in men with prostate cancer.
    Lancet Oncol. 2019 Jan 31. pii: S1470-2045(18)30863.
    PubMed     Text format    


    Nat Rev Urol

  45. STONE L
    Mitochondrial metabolism: a target in AR-driven disease.
    Nat Rev Urol. 2019;16:1.
    PubMed     Text format    


    Oncogene

  46. ZANG G, Mu Y, Gao L, Bergh A, et al
    PKCzeta facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model.
    Oncogene. 2019 Jan 31. pii: 10.1038/s41388-019-0722.
    PubMed     Text format     Abstract available

  47. ZHOU F, Gao S, Han D, Han W, et al
    TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.
    Oncogene. 2019 Feb 4. pii: 10.1038/s41388-019-0730.
    PubMed     Text format     Abstract available


    PLoS One

  48. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos C, Fernandez-Navarro P, et al
    Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study.
    PLoS One. 2018;13:e0201750.
    PubMed     Text format     Abstract available

  49. JEGERLEHNER S, Chiolero A, Aujesky D, Rodondi N, et al
    Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?
    PLoS One. 2019;14:e0210434.
    PubMed     Text format     Abstract available

  50. ARAS O, Pearce G, Watkins AJ, Nurili F, et al
    An in-vivo pilot study into the effects of FDG-mNP in cancer in mice.
    PLoS One. 2018;13:e0202482.
    PubMed     Text format     Abstract available


    Prostate

  51. XU Y, Song Q, Pascal LE, Zhong M, et al
    DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
    Prostate. 2019 Feb 3. doi: 10.1002/pros.23773.
    PubMed     Text format     Abstract available

  52. XUE YN, Yu BB, Liu YN, Guo R, et al
    Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
    Prostate. 2019 Feb 3. doi: 10.1002/pros.23772.
    PubMed     Text format     Abstract available


    Urology

  53. TANIGUCHI H, Kawakita S, Kinoshita H, Murota T, et al
    Testosterone Profiles after Brachytherapy for Localized Prostate Cancer.
    Urology. 2019 Feb 1. pii: S0090-4295(19)30089.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: